Tuberous sclerosis complex: Management
- James Owens, MD, PhD
James Owens, MD, PhD
- Associate Professor of Neurology
- Adjunct Associate Professor of Pediatrics
- University of Washington School of Medicine
- John B Bodensteiner, MD
John B Bodensteiner, MD
- Senior Associate Consultant in Child and Adolescent Neurology
- Mayo Clinic College of Medicine
- Section Editors
- Marc C Patterson, MD, FRACP
Marc C Patterson, MD, FRACP
- Section Editor — Pediatric Neurology
- Professor of Neurology, Pediatrics, and Medical Genetics
- Chair, Division of Child and Adolescent Neurology
- Mayo Clinic College of Medicine
- Helen V Firth, DM, FRCP, DCH
Helen V Firth, DM, FRCP, DCH
- Section Editor — Genetics
- Consultant Clinical Geneticist
- Addenbrooke's Hospital, Cambridge, UK
- Alberto S Pappo, MD
Alberto S Pappo, MD
- Section Editor — Pediatric Oncology
- Head of Solid Malignancies Program
- St. Jude Children's Research Hospital
Tuberous sclerosis complex (TSC) is an inherited neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems, including developmental delay and multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney, and skin. The expression of the disease varies substantially among individuals and within families. Some individuals with TSC may demonstrate only dermatologic features of the disease while others may develop more serious neurologic or systemic manifestations.
The management and prognosis of TSC will be reviewed here. Other aspects of TSC are discussed elsewhere. (See "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis" and "Renal manifestations of tuberous sclerosis complex" and "Pulmonary involvement in tuberous sclerosis complex".)
The management of TSC is directed at its neurologic and systemic manifestations, which include seizures, TSC-associated neuropsychiatric disorders, brain tumors, skin lesions, renal disease, pulmonary disease, cardiac involvement, and an increased risk of malignant tumors. Information regarding baseline evaluations, ongoing surveillance, and therapeutic interventions for these problems is provided in the sections that follow. Ideally, children with TSC should be cared for by specialized TSC clinics that have been established in many countries to address the medical needs and psychosocial challenges of affected patients, their families and caregivers .
Epilepsy — The most common and difficult aspect of management in TSC is the detection and treatment of seizures (see "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis", section on 'Seizures').
Monitoring — Many children with TSC develop focal seizures and infantile spasms during infancy. Therefore, international TSC guidelines recommend that parents should be educated to recognize these types of seizures even if none have occurred at the time of initial diagnosis . In addition, all pediatric patients with TSC should have a baseline electroencephalography (EEG) even if seizures are not evident. Children who have an abnormal EEG, particularly those with features of TSC-associated neuropsychiatric disorders, should have a follow-up 24-hour video EEG to look for subclinical seizure activity or epileptiform discharges .
- Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:255.
- Wu JY, Peters JM, Goyal M, et al. Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. Pediatr Neurol 2016; 54:29.
- Mytinger JR, Joshi S, Pediatric Epilepsy Research Consortium, Section on Infantile Spasms. The current evaluation and treatment of infantile spasms among members of the Child Neurology Society. J Child Neurol 2012; 27:1289.
- Gaily E. Vigabatrin monotherapy for infantile spasms. Expert Rev Neurother 2012; 12:275.
- Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51:1236.
- Elliott RE, Carlson C, Kalhorn SP, et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav 2009; 16:454.
- Major P, Thiele EA. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav 2008; 13:357.
- Zamponi N, Petrelli C, Passamonti C, et al. Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. Pediatr Neurol 2010; 43:29.
- Parain D, Penniello MJ, Berquen P, et al. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol 2001; 25:213.
- Avellino AM, Berger MS, Rostomily RC, et al. Surgical management and seizure outcome in patients with tuberous sclerosis. J Neurosurg 1997; 87:391.
- Karenfort M, Kruse B, Freitag H, et al. Epilepsy surgery outcome in children with focal epilepsy due to tuberous sclerosis complex. Neuropediatrics 2002; 33:255.
- Lachhwani DK, Pestana E, Gupta A, et al. Identification of candidates for epilepsy surgery in patients with tuberous sclerosis. Neurology 2005; 64:1651.
- Chandra PS, Salamon N, Huang J, et al. FDG-PET/MRI coregistration and diffusion-tensor imaging distinguish epileptogenic tubers and cortex in patients with tuberous sclerosis complex: a preliminary report. Epilepsia 2006; 47:1543.
- Jarrar RG, Buchhalter JR, Raffel C. Long-term outcome of epilepsy surgery in patients with tuberous sclerosis. Neurology 2004; 62:479.
- Jansen FE, van Huffelen AC, Algra A, van Nieuwenhuizen O. Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia 2007; 48:1477.
- Wu JY, Salamon N, Kirsch HE, et al. Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex. Neurology 2010; 74:392.
- Madhavan D, Schaffer S, Yankovsky A, et al. Surgical outcome in tuberous sclerosis complex: a multicenter survey. Epilepsia 2007; 48:1625.
- Muzykewicz DA, Costello DJ, Halpern EF, Thiele EA. Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG. Epilepsia 2009; 50:290.
- French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388:2153.
- Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004; 63:1457.
- Ouyang T, Zhang N, Benjamin T, et al. Subependymal giant cell astrocytoma: current concepts, management, and future directions. Childs Nerv Syst 2014; 30:561.
- Torres OA, Roach ES, Delgado MR, et al. Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 1998; 13:173.
- Beaumont TL, Limbrick DD, Smyth MD. Advances in the management of subependymal giant cell astrocytoma. Childs Nerv Syst 2012; 28:963.
- Kim SK, Wang KC, Cho BK, et al. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol 2001; 52:217.
- de Ribaupierre S, Dorfmüller G, Bulteau C, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 2007; 60:83.
- Berhouma M. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr 2010; 6:103.
- Kotulska K, Borkowska J, Roszkowski M, et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol 2014; 50:307.
- Matsumura H, Takimoto H, Shimada N, et al. Glioblastoma following radiotherapy in a patient with tuberous sclerosis. Neurol Med Chir (Tokyo) 1998; 38:287.
- Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol 2009; 39 Suppl 1:S27.
- Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43:289.
- Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59:490.
- Kohrman MH. Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol 2012; 46:267.
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125.
- Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801.
- Sasongko TH, Ismail NF, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev 2016; 7:CD011272.
- U.S. Food and Drug Admnistration. Everolimus (Accelerated Approval). www.fda.gov/AboutFDA/CentersOffices/CDER/ucm231967.htm (Accessed on November 02, 2010).
- Tran LH, Zupanc ML. Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature. Pediatr Neurol 2015; 53:23.
- Franz DN, Agricola K, Mays M, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol 2015; 78:929.
- Sadowski K, Kotulska K, Schwartz RA, Jóźwiak S. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review. J Eur Acad Dermatol Venereol 2016; 30:586.
- Jóźwiak S, Sadowski K, Kotulska K, Schwartz RA. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatr Neurol 2016; 61:21.
- Hallett L, Foster T, Liu Z, et al. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin 2011; 27:1571.
- de Vries P, Humphrey A, McCartney D, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry 2005; 14:183.
- Teng JM, Cowen EW, Wataya-Kaneda M, et al. Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. JAMA Dermatol 2014; 150:1095.
- Tyburczy ME, Wang JA, Li S, et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet 2014; 23:2023.
- Papadavid E, Markey A, Bellaney G, Walker NP. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br J Dermatol 2002; 147:337.
- Weinberger CH, Endrizzi B, Hook KP, Lee PK. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser. Dermatol Surg 2009; 35:1849.
- Weiss ET, Geronemus RG. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis. Lasers Surg Med 2010; 42:357.
- Balestri R, Neri I, Patrizi A, et al. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex. J Eur Acad Dermatol Venereol 2015; 29:14.
- Muzic JG, Kindle SA, Tollefson MM. Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin. JAMA Dermatol 2014; 150:1024.
- Wataya-Kaneda M, Tanaka M, Yang L, et al. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex. JAMA Dermatol 2015; 151:722.
- Whitehead LC, Gosling V. Parent's perceptions of interactions with health professionals in the pathway to gaining a diagnosis of tuberous sclerosis (TS) and beyond. Res Dev Disabil 2003; 24:109.
- Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol 2002; 168:1315.
- Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991; 66:792.
- - Monitoring
- - Seizure control
- - Refractory epilepsy
- Brain lesions
- - Brain imaging
- - Brain tumor treatment
- - Everolimus and mTOR inhibitors
- Cognitive and behavioral problems
- Skin lesions
- Dental and oral lesions
- Renal disease
- Pulmonary disease
- Cardiac problems
- Ophthalmologic evaluation
- Causes of death
- SUMMARY AND RECOMMENDATIONS